NEW YORK, NY / ACCESSWIRE / November 11, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.
Pintec Technology Holdings Limited (NASDAQ:PT)
This lawsuit is on behalf of shareholders who purchased PT securities pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's October 2018 initial public offering.
A class action has commenced on behalf of certain shareholders in Pintec Technology Holdings Limited. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the Company erroneously recorded revenue earned from certain technical service fee on a net basis, rather than a gross basis; (2) there were material weaknesses in Pintec's internal control over financial reporting related to cash advances outside the normal course of business to Jimu Group, a related party, and to a non-routine loan financing transaction with a third-party entity, Plutux Labs; (3) as a result of the foregoing, the Company's financial results for fiscal 2017 and 2018 had been misstated; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
Shareholders may find more information at https://securitiesclasslaw.com/securities/pintec-technology-holdings-limited-loss-submission-form/?id=10867&from=1
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
Investors Affected : February 28, 2020 - August 18, 2020
A class action has commenced on behalf of certain shareholders in BioMarin Pharmaceutical Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) differences between the Phase 1/2 and Phase 3 study of valoctocogene roxaparvovec, an investigational adenoassociated virus gene therapy, limited the reliability of the Phase 1/2 study to support valoctocogene roxaparvovec's durability of effect; (ii) as a result, it was foreseeable that the U.S. Food and Drug Administration would not approve the Biologics License Application for valoctocogene roxaparvovec without additional data; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.
Shareholders may find more information at https://securitiesclasslaw.com/securities/biomarin-pharmaceutical-inc-loss-submission-form/?id=10867&from=1
Royal Caribbean Cruises Ltd. (NYSE:RCL)
Investors Affected : February 4, 2020 - March 17, 2020
A class action has commenced on behalf of certain shareholders in Royal Caribbean Cruises Ltd. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Royal Caribbean misled investors to believe that any issue related to COVID-19 was relatively insignificant; (2) the Company falsely assured investors that bookings outside China were strong with no signs of a slowdown; (3) the Company was experiencing material declines in bookings globally due to customer concerns over COVID-19; and (5) the Company's ships were following grossly inadequate protocols that would foster the spread of COVID-19 and pose a substantial risk to passengers and crews.
Shareholders may find more information at https://securitiesclasslaw.com/securities/royal-caribbean-cruises-ltd-loss-submission-form/?id=10867&from=1
The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (212) 537-9430
Fax: (833) 862-7770
SOURCE: The Gross Law Firm